Although this study has confirmed that ITGA2 mediates lenvatinib resistance in hepatocellular carcinoma via the AKT/FOXO3A signaling pathway, several limitations remain, and future studies should focus on the following aspects for further expansion. The gene discussed is AKT1; the disease is hepatocellular carcinoma.